No connection

Search Results

ABBV vs ANIK

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
ANIK
Anika Therapeutics, Inc.
BEARISH
Price
$14.20
Market Cap
$204.8M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
ANIK
--
Forward P/E
ABBV
15.42
ANIK
35.5
P/B Ratio
ABBV
-146.66
ANIK
1.37
P/S Ratio
ABBV
6.5
ANIK
1.82
EV/EBITDA
ABBV
15.27
ANIK
-29.07

Profitability

Gross Margin
ABBV
71.46%
ANIK
56.56%
Operating Margin
ABBV
35.5%
ANIK
2.11%
Profit Margin
ABBV
4.0%
ANIK
-9.64%
ROE
ABBV
137.96%
ANIK
-6.71%
ROA
ABBV
9.59%
ANIK
-3.52%

Growth

Revenue Growth
ABBV
9.1%
ANIK
0.0%
Earnings Growth
ABBV
-88.7%
ANIK
--

Financial Health

Debt/Equity
ABBV
--
ANIK
0.18
Current Ratio
ABBV
0.72
ANIK
4.72
Quick Ratio
ABBV
0.47
ANIK
3.71

Dividends

Dividend Yield
ABBV
3.05%
ANIK
--
Payout Ratio
ABBV
490.15%
ANIK
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
ANIK BEARISH

ANIK's Piotroski F-Score of 2/9 indicates weak financial health, with significant red flags in profitability and cash flow. The company reports negative net income and ROE, despite a strong gross margin of 56.56%, suggesting operational inefficiencies. While the debt-to-equity ratio of 0.18 and high current ratio (4.72) point to solid liquidity, the lack of revenue growth (0% YoY) and absence of free cash flow undermine long-term sustainability. The stock trades at a forward P/E of 35.50, which is elevated relative to its lack of earnings growth, and the 63.8% 6-month rally appears speculative rather than fundamentals-driven. Analysts rate it 'strong_buy' with a target of $17.50, but this is not supported by core financial metrics.

Strengths
High gross margin (56.56%) indicates strong pricing power and cost control in production
Strong liquidity position with current ratio of 4.72 and quick ratio of 3.71
Low debt-to-equity ratio (0.18) suggests conservative capital structure
Risks
Piotroski F-Score of 2/9 signals poor financial health and high distress risk
Negative net profit margin (-9.64%) and ROE (-6.71%) indicate unprofitable operations
Zero revenue growth (0% YoY) despite a growing market cap, suggesting stagnation

Compare Another Pair

ABBV vs ANIK: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Anika Therapeutics, Inc. (ANIK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile